Genetic variants in endothelial nitric oxide synthase gene are modifiers of the hemolysis phenotype in Sickle Cell Anemia

Laura Aguiar1,2,3 Andreia Matos1,3 Ângela Gil1,3 Conceição Afonso4 Ligia Braga4 João Lavinha4 Paula Kjollerstrom4, Paula Faustino2,4 Manuel Bicho1,3, Ângela Inácio1,3

1Laboratório de Genética, Faculdade de Medicina da Universidade de Lisboa (FMUL), Lisboa
2Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisboa
3Instituto De Investigação Científica Benito Da Rocha Cabral (IICBRC), Lisboa
4Unidade de Hematologia do Hospital de Dona Estefânia (HDE), Lisboa

INTRODUCTION

Sickle Cell Anemia (SCA) is an autosomal recessive hereditary anemia characterized by the presence of hemoglobin S (Hb S). This disease is caused by a single mutation in the beta-globin gene with a corresponding amino acid substitution at the sixth position of the beta-globin chain. The easily ability of Hb S to polymerize in deoxygenated conditions gives rise to abnormal sickled red blood cells (Figure 1) (Rees et al, 2010). Vaso-occlusion and hemolytic anemia are the major features of this disease, however SCA patients present clinical and hematologic variability that cannot be only explained by the single mutation in the beta-globin gene. Others genetic modifiers and environmental effects are important in the clinical phenotype (Steinberg & Sebastiani, 2012).

The aim of this work was to determine the association between hematological or biochemical parameters and genetic variants from candidate genes, in SCA patients.

METHODS

Subjects: 26 paediatric SCA patients (mean age of 8.58 years) followed-up in Hospital de Dona Estefânia, in Lisbon.

Hematological or biochemical parameters: Hb S, total Hb, red cell distribution width (RDW), leukocytes, neutrophils, transmembrane reductase, methemoglobin reductase, serum lactate dehydrogenase (LDH), total bilirubin and reticulocyte count.

Candidate genes: BCL11A, HBA, HBO cluster, HMOX1, eNOS, MTHFR and MPO.

Statistical analysis: Association studies were performed using T test/ ANOVA parametric tests (Hb S, total Hb, RDW, neutrophils, transmembrane reductase, methemoglobin reductase and reticulocyte count) or Mann-Whitney/Kruskal-Wallis non-parametric tests (total bilirubin, leukocytes and LDH), all performed with SPSS 22.0 software.

RESULTS

• Association studies between candidate genotypes and hematological or biochemical parameters were performed.
• The following significant associations were observed (Table 1 and 2, Figure 2 and 3).
• Our results show a significant statistical association between two eNOS single nucleotide polymorphisms (SNPs) and two haemolysis parameters. Both the rs2070744_TT and the rs1799983_GG genotypes are associated with an increased reticulocyte count (p = 0.02 and 0.01, respectively) and higher serum LDH level (p = 0.04 and 0.04, respectively).

Table 1 - Association between the parameters reticulocyte count and LDH and rs2070744 genotypes (TT and CT) at eNOS gene

<table>
<thead>
<tr>
<th>Parameters</th>
<th>TT (%)</th>
<th>CT (%)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reticulocyte count (%)</td>
<td>9.56 ± 3.43 (13)</td>
<td>6.12 ± 2.50 (10)</td>
<td>0.021</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>490.00; 410-793 (7)</td>
<td>371.50; 328-451 (4)</td>
<td>0.044</td>
</tr>
</tbody>
</table>

*1 M test - Mean ± standard deviation (n – sample size)
*2 Mann-Whitney test - Median: minimum - maximum (n – sample size)

Table 2 - Association between the parameters reticulocyte count and LDH and rs1799983 genotypes (GG and CT/TT) at eNOS gene

<table>
<thead>
<tr>
<th>Parameters</th>
<th>GG (%)</th>
<th>GT/TT (%)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reticulocyte count (%)</td>
<td>9.20 ± 3.21 (17)</td>
<td>4.53 ± 1.75 (5)</td>
<td>0.011</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>490.00; 410-793 (7)</td>
<td>371.50; 328-451 (4)</td>
<td>0.044</td>
</tr>
</tbody>
</table>

*1 M test - Mean ± standard deviation (n – sample size)
*2 Mann-Whitney test - Median: minimum - maximum (n – sample size)

CONCLUSIONS

Our findings suggest that polymorphisms in the eNOS gene may act as genetic modifiers of the haemolysis, which could provide utility for the prediction of increased susceptibility to haemolysis-related complications.

Furthermore, our results reinforce the importance of nitric oxide (NO) bioactivity in SCA. We presume that NO, and possible its precursors such as L-arginine or L-citrulline, might be used as pharmacological tools to improve the quality of life of these patients.

References